MetGen Oy
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
MetGen Oy - overview
Location
Kaarina, -, Finland
Primary Industry
Biotechnology
About
MetGen Oy is a Finnish company that specializes in biorefinery solutions, creating enzyme products that transform biomass into valuable bio-based materials, thereby promoting sustainable industrial practices. MetGen Oy is focused on providing biorefinery solutions that enhance biochemical processes. Founded in Kaarina, Finland, the company has seen strategic changes in its operations over the years. Notably, it raised EUR 4.
80 mn in a SERIES A funding round led by Sofinnova Partners on June 1, 2016. The company's total funding to date amounts to EUR 4. 80 mn, supported by investors including Finnvera, HST Partners Oy, Loudspring, and Tesi. The founder's specific background is not detailed in the available information.
MetGen specializes in comprehensive biorefinery solutions that optimize biochemical processes by converting biomass into high-value bio-based products. The company’s core offerings include advanced enzyme solutions tailored for industrial applications, particularly in protein engineering and enzyme production. Their services cater to a diverse clientele, including biorefineries aiming to enhance production efficiency and reduce fossil fuel reliance. MetGen's products, including METNIN™ bioesters and METNIN™ nanopolyols, are integral to their offerings, targeting markets across Europe, North America, and parts of Asia.
In 2023, MetGen generated revenue of EUR 1,232,164. 90 with an EBITDA of EUR -1,062,983. 90. The company operates on a B2B model, utilizing partnerships and licensing agreements in the biorefineries and bio-based materials sector, often establishing long-term contracts with clients for customized solutions.
MetGen plans to utilize its recent funding to develop new enzyme products and expand into additional markets, particularly targeting regions with emerging bioeconomies. The funding raised in 2016 is expected to support these initiatives as they work on product innovations and enhancing service offerings to meet the growing demand in the biorefinery sector.
Current Investors
Innovestor, Sofinnova Partners, Tesi
Primary Industry
Biotechnology
Sub Industries
Biomass, Biopolymers, Bioinformatics
Website
www.metgen.fi
Company Stage
Series A
Total Amount Raised
Subscriber access only
MetGen Oy - timeline of key events
MetGen Oy - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 119,000 | 120,380 | 100,141.6 | 45,090 | 7,500 | 17,600 | 172,010 | 329,157.5 | 690,388.6 | 678,278.8 | 781,074.5 | - | - | - |
| % Revenue Growth (YoY) | - | 1.2% | (16.8%) | (55.0%) | (83.4%) | 134.7% | 877.3% | 91.4% | 109.7% | (1.8%) | 15.2% | - | - | - |
| EBITDA (USD) | (173,611.6) | (241,344.8) | (351,631.5) | (1,202,190.8) | (1,789,286.6) | (945,615) | (784,145.6) | (826,481.9) | (927,201.4) | (1,034,047) | (903,103.6) | - | - | - |
| Operating Income (USD) | (212,588.8) | (282,905.7) | (390,346.4) | (1,289,088.3) | (1,910,733.9) | (1,165,195.5) | (982,090.2) | (1,012,510.5) | (1,180,968.8) | (1,348,345.9) | (1,109,738.9) | - | - | - |
| Operating Margin | (178.6%) | (235.0%) | (389.8%) | (2858.9%) | (25476.5%) | (6620.4%) | (570.9%) | (307.6%) | (171.1%) | (198.8%) | (142.1%) | - | - | - |
| % EBITDA Margin | (145.9%) | (200.5%) | (351.1%) | (2666.2%) | (23857.2%) | (5372.8%) | (455.9%) | (251.1%) | (134.3%) | (152.5%) | (115.6%) | - | - | - |
| NET Income (USD) | (209,492.4) | (297,001.5) | (576,285) | (1,293,077.6) | (1,914,990.4) | (1,187,582.9) | (1,004,163.3) | (1,035,627.4) | (1,188,457.5) | (1,354,313.2) | (1,115,417.2) | - | - | - |
| % Net Margin | (176.0%) | (246.7%) | (575.5%) | (2867.8%) | (25533.2%) | (6747.6%) | (583.8%) | (314.6%) | (172.1%) | (199.7%) | (142.8%) | - | - | - |
MetGen Oy - employee data
MetGen Oy - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member | BM | ||||||
| Member of Board of Directors | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.